Thermo Fisher Scientific Unveils New Solutions Supporting Research Workflows at ASMS 2024

New analytical instruments and workflow capabilities improve productivity, reliability and sensitivity of discovery, translational and clinical research

ANAHEIM, Calif.--(BUSINESS WIRE)--To help accelerate the promise of precision medicine, Thermo Fisher Scientific today unveiled its new solutions accelerating research workflows at the annual American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, in Anaheim, California. The new mass spectrometry and chromatography instruments and software solutions enable customers to unlock deeper analytical insights with built-for-purpose flexibility, improving productivity, efficiency, and accelerating translational research workflows.

“As we look to best serve our customers, we noted a need for built-for-purpose solutions designed for their unique application areas that help them take key findings from compounds to clinical research,” said August Specht, vice president, R&D, chromatography and mass spectrometry, Thermo Fisher Scientific. “Pairing our industry-leading instruments with best-in-class software solutions and workflows helps deliver on this promise, empowering key research findings of today to translate into the precision medicines of tomorrow.”

Accelerating Research from Discovery to Validation

Complementing the power that the Thermo Scientific Orbitrap™ Astral™ mass spectrometer (MS) brings to scientific discovery, the Thermo Scientific Stellar™ MS is innovating translational omics research at an unprecedented scale. The Stellar MS advances biomarker verification, delivering fast and sensitive quantitation to confirm and verify all biomarkers of significance. With a unique design that combines the quantitative performance of a triple quadrupole with the single cell sensitivity of linear ion trap analyzers, the Stellar MS achieves 10X the quantitative sensitivity for 5X more compounds at scale compared to existing technologies.

To supplement this need for scale as liquid chromatography-mass spectrometry (LC-MS)-based omics gains popularity, the new Thermo Scientific Vanquish™ Neo ultra-high performance liquid chromatography (UHPLC) system Tandem Direct Injection workflow helps proteomics labs rapidly generate high-quality, biologically relevant data. The Tandem Direct Injection workflow increases sample throughput and provides up to a ~70% increase in samples per day, decreases carryover and yields more than 90% mass spectrometer utilization, enabling high-throughput LC separation as a perfect companion to high-throughput mass spectrometers such as Orbitrap Astral MS or Stellar MS.

The Next-Generation Workflow Starts with Built-for-Purpose Technology

To help accelerate research, the company unveiled three new built-for-purpose editions of the Thermo Scientific Orbitrap Ascend Editions Tribrid™ mass spectrometers with unique capabilities tailored to specific application areas. The three new editions include the MultiOmics Edition, Structural Biology Edition, and BioPharma Edition, featuring new hardware for a Native MS option and a dry pump with improved sustainability and performance.

Now, scientists can quantify more samples at lower concentrations using intelligent acquisition and achieve greater coverage that delivers ultimate experimental throughput, versatility, and ease of use, empowering scientists to make breakthrough discoveries even more efficiently.

As a complement to the Orbitrap Ascend Editions Tribrid MS, customers will be able to experience the power of higher multiplexing, later this year, with the launch of the Thermo Scientific TMTpro 32plex Label Reagents, enabling analysis of up to 32 samples in a single LC-MS injection. This higher level of multiplexing is especially beneficial for applications requiring higher throughput and depth of coverage such as chemoproteomics, peptidomics, and single cell proteomics.

Establishing a Holistic, Reliable & Secure Software Ecosystem

As laboratories are focused on increasing their productivity, the need for software that seamlessly connects data, applications, and instruments has never been greater. The Thermo Scientific Ardia™ platform, supports scientists’ end-to-end workflows and centralizes data and instrument management across multiple chromatography and mass spectrometry systems. The company has now added new capabilities centered on security, connectivity and openness, with improved support for the Orbitrap Astral MS and Stellar MS.

The newly connected Compound Discoverer 3.4 software and support for third party Skyline.ms software, along with updates to Ardia Core 1.1 SW, Proteome Discoverer 3.2 software, and Ardia Platform Data Sync tool 1.1 software, bring enterprise-level data handling capabilities that enable users to manage, process, and share data in ways not previously possible. The new levels of data security and connectivity give scientists the freedom of choice for their data handling needs, empowering them to break down silos and better understand new diagnostics and therapies even faster.

For more information on the Thermo Fisher solutions exhibited at ASMS 2024, please visit www.thermofisher.com/ASMS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.